House & Home
House and Home
House and Home
Tue, November 9, 2010
Toyota Motor Corp., King Pharmaceuticals Inc., Bristol-Myers Squibbsa?, Johnson & Johnson and Pfizer
CHICAGO--([ BUSINESS WIRE ])--Zacks.com Analyst Blog features: Toyota Motor Corp. (NYSE: [ TM ]), King Pharmaceuticals Inc. (NYSE: [ KG ]), Bristol-Myers Squibbsa™ (NYSE: [ BMY ]), Johnson & Johnson (NYSE: [ JNJ ]) and Pfizer (NYSE: [ PFE ]).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: [ http://at.zacks.com/?id=4579 ]
Here are highlights from Mondaya™s Analyst Blog:
Toyotaa™s Profit Quintuples
Toyota Motor Corp. (NYSE: [ TM ]) revealed a fivefold increase in profit to 115.5 billion ($1.34 billion) or 31.47 per share (37 cents) in the second quarter of its fiscal 2011 ended March 31, 2011 from 22.19 billion ($258.26 million) or 6.96 per share (8 cents) in the same quarter of previous fiscal year. The profit was boosted by marketing strategy as well as cost reduction measures incorporated by the company during the quarter.
Consolidated revenues in the quarter ascended 6% to 4.81 trillion ($55.98 billion) on the back of a 10% rise in global sales volume to 1.9 million units. Vehicle sales declined marginally by 2,509 units to 514,882 units in North America and 19% or 41,496 units to 180,878 units in Europe. Meanwhile, sales rose 18% to 585,496 units in Japan, 27% to 289,826 units in Asia, and 22% to 324,189 units on Other regions.
Operating profit almost doubled to 111.46 billion ($1.30 billion) from 58 billion ($675.05 million) in the second quarter of fiscal 2010. The rise in operating profit was attributable to positive impacts from marketing efforts and cost reduction measures, offset partially by unfavorable exchange rate.
King Pharma Disappoints
In a filing with the US Securities and Exchange Commission (SEC), King Pharmaceuticals Inc. (NYSE: [ KG ]) reported third-quarter earnings of 16 cents per share, a penny below the year-ago earnings. The Zacks Consensus Estimate was 19 cents.
Revenues fell 19.2% to $374.5 million mainly due to the lackluster performance of several key products and the entry of two generic versions of Skelaxin. Revenues, however, exceeded the Zacks Consensus Estimate by $7.5 million.
Quarter in Detail
King Pharma's branded Pharmaceuticals segment declined 43.3% with revenues coming in at $160.8 million. Revenues of almost all key products declined from the year-ago period.
Thrombin-JMI sales declined 25.9% to $32.2 million. We expect Thrombin-JMI sales to continue declining due to tough competition in the form of Bristol-Myers Squibbsa™ (NYSE: [ BMY ]) Recothrom and Johnson & Johnsona™s (NYSE: [ JNJ ]) Evithrom.
Meanwhile, Skelaxin (metaxalone), which posted sales of $91 million in the first quarter of 2010, saw a huge drop in sales due to the entry of two generic versions early in the second quarter. Skelaxin sales plunged to $6.8 million in the third quarter of 2010, down from $102.1 million in the year-ago quarter.
According to IMS weekly prescription data, for the week ending October 22, 2010, generic competitors captured about 85% of the prescriptions in the metaxalone market. King Pharma received $25.2 million in the form of royalties from sales on the authorized generic version of Skelaxin.
Avinza revenues declined 11.4% to $27.3 million, mainly due to declining prescriptions (down 30.7%).
Embeda, obtained through King Pharma's acquisition of Alpharma, posted sales of $10.2 million, down 32% sequentially. Embeda was launched in the third quarter of 2009; revenues declined 9% from the year-ago period. Sales were affected by voluntary product recalls announced by King Pharma during the first half of 2010. These product recalls were due to post-manufacturing testing issues. Two more lots of Embeda have been recalled so far in the fourth quarter.
Flector Patch, another product obtained through the Alpharma acquisition, was the only product to record growth during the third quarter. An increase in wholesale inventory levels accompanied with a price increase taken earlier this year helped boost FlectorPatch sales to $42.4 million, up 5%. Prescriptions, however, declined 8.3% during the quarter.
Revenues from the Animal Health business were $92.7 million in the reported quarter, down 3.3%. The Animal Health business should provide positive cash flow and diversification.
We were pleased to see King Pharmaa™s Meridian Auto-Injector business continue to perform well. Third quarter revenues came in at $83.6 million, up 16.4%. Price increases, higher sales and royalties on EpiPen helped offset the impact of lower government orders. The company also signed a signed a new supply agreement with Dey Pharma, under which the EpiPen collaboration will run through 2020. Under the new contract, King Pharma will receive higher prices and royalties (effective January 1, 2010).
Operating expenses declined to $140 million. While selling, general and administrative expenses declined 15.8% to $114.3 million, research & development expenses increased 13.4% to $25.7 million.
King Pharma said that it remains on track to re-submit its marketing applications for opioid candidates, Remoxy and Acurox. While the Remoxy application should be re-submitted to the US Food and Drug Administration (FDA) by year-end, the marketing application for Acurox (without niacin) is scheduled to be re-submitted in the US in the first quarter of 2011.
Neutral on King Pharma
We currently have a Neutral recommendation on King Pharma, which is supported by a Zacks #3 Rank (short-term aHolda rating). In October 2010, King Pharma entered into an agreement with Pfizer (NYSE: [ PFE ]) whereby Pfizer will acquire King Pharma for $14.25 per share.
The offer price represents a 40% premium on King Pharmaa™s closing price as of October 11, 2010. The Boards of both companies have approved the deal, which is scheduled to close later this year/early next year.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: [ http://at.zacks.com/?id=5514 ].
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: [ http://at.zacks.com/?id=5516 ]
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at [ http://at.zacks.com/?id=4580 ].
Visit [ http://www.zacks.com/performance ] for information about the performance numbers displayed in this press release.
Follow us on Twitter: [ http://twitter.com/ZacksResearch ]
Join us on Facebook: [ http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts ]
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
